HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    
Learn more
Self Investors Wanted Today

Few spots available. Master Zacks' market-tripling Stock Picking Method in your home at our cost.
Opportunity ends Saturday, Nov. 21 >>
Quote:
Login Free Membership
Search:

 
Bear of the Day

Genomic Health, Inc. (GHDX)

By: Zacks Equity Research
October 30, 2009 | Comments: 1
Recommended this article (0)
GHDX
Print    Share

Genomic Health Inc.'s (GHDX - Analyst Report) lead product is Oncotype DX, which is used for early stage breast cancer patients to predict the likelihood of cancer recurrence.

Even though sales of Oncotype remain robust and the company remains optimistic about its prospects, we are highly concerned about the company's reliance on the product for growth. We believe that Genomic needs to expand its product portfolio in order to sustain growth.

Furthermore, we are also concerned about the company's weak pipeline. These concerns have caused us to downgrade the stock to Underperform.


Email
Print
Share
RSS
Rate Pos
Rate Neg
Comment
Read/Post Comments (1) | Recommended this article (0)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
11
days
ago
Karl Simpson wrote...
This looks like an interesting company and the Oncotype DX test seems to have proven a valuable test in Breast Cancer.
Link Post Comment
 Loading Report Abuse...
There was a problem reporting abuse for this comment. Please try back later.
[CLICK TO CLOSE X]
Please let us know why you believe this comment is in violation of our community guidelines. Our team will take the appropriate action.
 
<< Previous 5View AllNext 5 >>

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

More Zacks Links

Market Summary Nov 21, 2009 17:23 pm ET
DJIA 10318.16  -14.28 -0.14%
NASD 2146.04  -10.78 -0.50%
S&P 500 1091.38  -3.52 -0.32%
Sponsored Links

Top Zacks Features

Free Membership
Zacks Rank
Equity Research
Portfolio Tracker
Screening
Profit Tracks
Mutual Funds
Options
Zacks Video
Education
RSS Feed
Profit from the Pros

Subscription Services

Product Guide
Method for Trading
Chart Patterns Trader
DYM Trader
Growth Trader
Options Trader
Surprise Trader
Value Trader
Value Trader 2
Special Reports
Top 10 Stocks
Research Wizard
Zacks Premium
Zacks Elite
People & Picks
Zacks.com: About Zacks | Education | Advertise | Media | Careers | Contact Us | Services | Help | Disclaimer | Privacy Policy | Sitemap

Copyright 2009 Zacks Investment Research

Zacks Investment Research is one of the most highly regarded firms in the investment industry. The guiding principle behind our work is that there must be a good reason for brokerage firms to spend billions of dollars a year on stock research. Obviously, these investment experts know something special that may be indicative of the future direction of stock prices. From day one, we were determined to unlock that secret knowledge and make it available to our clients to help them improve their investment results.

NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.